Date: 2015-08-26
Type of information: Licensing agreement
Compound: Vero cell technology platform
Company: Takeda Pharmaceutical (Japan) Nanotherapeutics (USA - FL)
Therapeutic area: Infectious diseases
Type agreement: licensing commercialisation
Action mechanism:
Disease: pandemic and seasonal influenza
Details: * On August 26, 2015, Takeda Pharmaceutical Company and Nanotherapeutics announced an agreement providing Takeda with
expanded commercialization and technology access rights related to Nanotherapeutics’Vero cell technology platform – a cell culture-based platform for vaccine production which Nanotherapeutics acquired from Baxalta, formerly Baxter International’s BioScience division. In 2010, Takeda and Baxter entered into an agreement in which Takeda licensed from Baxter certain exclusive rights to the technology for the development of pandemic and seasonal influenza vaccines for the Japanese market. Takeda’s cell culture-based H5N1 and prototype vaccine for pandemic influenza was developed on this platform and was approved in Japan in March 2014. Takeda is currently developing a cell-based seasonal flu vaccine (TAK-850) on the same platform for use in Japan.
The agreement with Nanotherapeutics extinguishes Takeda’s remaining financial obligations under the initial agreement with Baxter. Additionally, Takeda gains rights to commercialize its pandemic and seasonal influenza vaccine products, based on the Vero cell technology platform, in certain regions outside of Japan and will have access to Vero cell technology and reagents for the development of vaccines beyond influenza.
Financial terms: Financial terms of the agreement were not disclosed.
Latest news:
